Clovis Oncology Inc

NASDAQ:CLVS   3:59:59 PM EDT
2.45
-0.26 (-9.78%)
5:02:42 PM EDT: $2.45 +0.01 (+0.20%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)317.79M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$40.04 Million
Adjusted EPS-$0.56
See more estimates
10-Day MA$2.61
50-Day MA$3.09
200-Day MA$4.62
See more pivots

Clovis Oncology Inc Stock, NASDAQ:CLVS

5500 Flatiron Parkway, Suite 100, Boulder, Colorado 80301
United States of America
Phone: +1.303.625.5000
Number of Employees: 429

Description

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.